Clinical Trials
70 trialsNCT05221645 2026-05-15
P+R-ICE
University of Southampton
Phase 2 Active not recruiting
NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT02106988 2026-04-14
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05821088 2025-11-20
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03016871 2025-10-20
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06905509 2025-09-29
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
University of California, Davis
Phase 2 Recruiting
NCT04665765 2025-09-03
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07081022 2025-08-21
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT02393157 2025-08-08
O-ICE
New York Medical College
Phase 2 Recruiting
NCT00878254 2025-07-23
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
University of Miami
Phase 2 Completed
NCT02329080 2025-07-08
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT04189952 2025-05-31
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
Phase 2 Terminated
NCT01979536 2024-04-30
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00007865 2023-12-27
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00039130 2023-08-21
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00274924 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03077828 2023-06-02
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT00712582 2022-06-21
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01481272 2021-12-27
PLRG8
Polish Lymphoma Research Group
Phase 2 Completed
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT00324467 2021-07-22
LYTPET
British Columbia Cancer Agency
Phase 2 Unknown
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT02445404 2020-10-22
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
Samsung Medical Center
Phase 2 Unknown
NCT02544425 2020-10-22
VIDL+ASCT
Samsung Medical Center
Phase 2 Unknown
NCT01329900 2020-07-08
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00392990 2019-10-15
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
Northwestern University
Phase 2 Completed
NCT02592876 2019-05-17
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT00809341 2018-09-25
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00002865 2018-08-10
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00392834 2018-06-06
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT01097057 2018-01-23
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03383406 2017-12-26
IVAM
Asan Medical Center
Phase 2 Unknown
NCT00504751 2017-04-07
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Weill Medical College of Cornell University
Phase 2 Completed
NCT00039195 2016-08-10
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002494 2016-07-04
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02412267 2016-03-23
DLBL
National Cancer Centre, Singapore
Phase 2 Completed
NCT00255723 2016-02-01
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003631 2016-01-25
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00280878 2016-01-15
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Bayside Health
Phase 2 Completed
NCT00163761 2016-01-08
Efficacy Study of Outpatient Therapy for Lymphoma
Bayside Health
Phase 2 Completed
NCT00588094 2015-12-04
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00450801 2015-11-10
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
University of Miami
Phase 2 Completed
NCT00529503 2015-02-25
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Seagen Inc.
Phase 2 Terminated
NCT00040690 2013-12-19
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00292695 2013-10-30
A Phase II Study of Nasal NK/T-cell Lymphoma
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT00058461 2013-10-08
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00669812 2013-08-26
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown